The Conversation (0)
BioLineRx today announced its financial results for the third quarter of 2016, which ended on September 30, 2016.
BioLineRx (NASDAQ:BLRX), a biopharmaceutical company that focuses on in-licensing, today announced its financial results for the third quarter of 2016, which ended on September 30, 2016.
According to the press release:
“The Company’s operating loss for the three months ended September 30, 2016amounted to $4.5 million, compared with an operating loss of $3.6 million for the corresponding 2015 period. The Company’s operating loss for the nine months ended September 30, 2016 amounted to $12.1 million, similar to the comparable period in 2015.”
CEO Philip A. Serlin said the following:
“We are excited about our prospects ahead and are focused on achieving our expected milestones for 2017 and beyond. With $39 million of cash on hand, we remain well positioned to carry out our operational plans for the next few year.”